FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2691-2694 June 26, 2003 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Rituximab is effective in B-cell lymphomas either as a single agent or combined with chemotherapy. Its toxic effects are generally mild and transient.^1,2 We report eight cases of acute and severe neutropenia that occurred 8 to 23 weeks after the administration of rituximab for non-Hodgkin's lymphoma or chronic lymphocytic leukemia. All patients had a normal polymorphonuclear-cell count before rituximab treatment (Table 1). None of the known causes of neutropenia were found. Previous treatment with rituximab two to four months before the development of neutropenia was a common factor in these eight patients, which suggests that . . . [Full Text of this Article]

This article has been cited by other articles:

• Illidge, T. M., Bayne, M., Brown, N. S., Chilton, S., Cragg, M. S., Glennie, M. J., Du, Y., Lewington, V., Smart, J., Thom, J., Zivanovic, M., Johnson, P. W. M. (2009). Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113: 1412-1421 [Abstract] [Full Text]  
• Marotte, H, Paintaud, G, Watier, H, Miossec, P (2008). Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis 67: 893-894 [Full Text]  
• Gonzalez-Barca, E., Domingo-Domenech, E., Capote, F. J., Gomez-Codina, J., Salar, A., Bailen, A., Ribera, J.-M., Lopez, A., Briones, J., Munoz, A., Encuentra, M., Fernandez de Sevilla, A., on behalf of the GEL/TAMO (Grupo Espanol de Linfom, (2007). Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. haematol 92: 1489-1494 [Abstract] [Full Text]  
• Martin, P., Furman, R. R., Coleman, M., Leonard, J. P. (2007). Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma. Clin. Cancer Res. 13: 5636s-5642s [Abstract] [Full Text]  
• Terrier, B., Ittah, M., Tourneur, L., Louache, F., Soumelis, V., Lavie, F., Casadevall, N., Candon, S., Hummel, A., Mariette, X., Buzyn, A. (2007). Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. haematol 92: e20-e23 [Abstract] [Full Text]  
• Nitta, E, Izutsu, K, Sato, T, Ota, Y, Takeuchi, K, Kamijo, A, Takahashi, K, Oshima, K, Kanda, Y, Chiba, S, Motokura, T, Kurokawa, M (2007). A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 18: 364-369 [Abstract] [Full Text]  
• Ravandi, F., Jorgensen, J. L., O'Brien, S. M., Verstovsek, S., Koller, C. A., Faderl, S., Giles, F. J., Ferrajoli, A., Wierda, W. G., Odinga, S., Huang, X., Thomas, D. A., Freireich, E. J., Jones, D., Keating, M. J., Kantarjian, H. M. (2006). Eradication of minimal residual disease in hairy cell leukemia. Blood 107: 4658-4662 [Abstract] [Full Text]  
• Choquet, S., Leblond, V., Herbrecht, R., Socie, G., Stoppa, A.-M., Vandenberghe, P., Fischer, A., Morschhauser, F., Salles, G., Feremans, W., Vilmer, E., Peraldi, M.-N., Lang, P., Lebranchu, Y., Oksenhendler, E., Garnier, J. L., Lamy, T., Jaccard, A., Ferrant, A., Offner, F., Hermine, O., Moreau, A., Fafi-Kremer, S., Morand, P., Chatenoud, L., Berriot-Varoqueaux, N., Bergougnoux, L., Milpied, N. (2006). Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 107: 3053-3057 [Abstract] [Full Text]  
• Dimopoulou, I., Bamias, A., Lyberopoulos, P., Dimopoulos, M. A. (2006). Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 17: 372-379 [Abstract] [Full Text]  
• Dunleavy, K., Hakim, F., Kim, H. K., Janik, J. E., Grant, N., Nakayama, T., White, T., Wright, G., Kwak, L., Gress, R., Tosato, G., Wilson, W. H. (2005). B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106: 795-802 [Abstract] [Full Text]  
• Miles, S. A., McGratten, M. (2005). Persistent Panhypogammaglobulinemia After CHOP-Rituximab for HIV-Related Lymphoma. JCO 23: 247-248 [Full Text]  
• Ruegg, S. J., Fuhr, P., Steck, A. J. (2004). Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63: 2178-2179 [Abstract] [Full Text]